Evaxion A/S (EVAX) Stock Price, News & Analysis

Company Overview

Evaxion A/S is a Denmark-based biotechnology company that develops immunotherapies and vaccines using artificial intelligence. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease targets and support the development of treatments tailored to individual patients or specific pathogens.

The company’s research has focused primarily on personalized cancer vaccines and vaccines for infectious diseases. Its pipeline has included EVX-01, an individualized cancer immunotherapy candidate intended to stimulate a patient’s immune system to recognize and attack tumor-specific targets, as well as additional programs directed at cancer and infectious diseases.

Evaxion was founded in Denmark and conducts its research and development activities from the country, serving the international biotechnology and pharmaceutical markets. The company’s shares trade in the United States under the symbol EVAX.

Key Stats

• Today's Range: $3.19 to $3.35
• 50-Day Range: $2.79 to $3.40
• 52-Week Range: $2.77 to $12.15
• Volume: 55,694 shs
• Average Volume: 94,482 shs
• Market Capitalization: $29.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Evaxion A/S Stock Analysis - MarketRank™

Evaxion A/S scored higher than 54% of companies evaluated by MarketBeat, and ranked 459th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evaxion A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Evaxion A/S has a consensus price target of $11.00, representing about 239.5% upside from its current price of $3.24.

Amount of Analyst Coverage

Evaxion A/S has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evaxion A/S is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evaxion A/S is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evaxion A/S has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.11% of the float of Evaxion A/S has been sold short.

Short Interest Ratio / Days to Cover

Evaxion A/S has a short interest ratio ("days to cover") of 1.15, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evaxion A/S has recently decreased by 4.83%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evaxion A/S does not currently pay a dividend.

Dividend Growth

Evaxion A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.89

News Sentiment

Evaxion A/S has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Evaxion A/S this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Evaxion A/S to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evaxion A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.64% of the stock of Evaxion A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.04% of the stock of Evaxion A/S is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EVAX
• CIK: 1828253
• Web: www.evaxion.ai
• Phone: 45-5353-1850
• Fax: N/A
• Employees: 46
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Evaxion A/S: $11.00
• High Price Target: $16.00
• Low Price Target: $9.00
• Potential Upside/Downside: +239.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.71 million
• Net Margins: N/A
• Pretax Margin: -128.07%
• Return on Equity: -61.43%
• Return on Assets: -34.23%

Debt

• Debt-to-Equity Ratio: 0.69
• Current Ratio: 5.06
• Quick Ratio: 5.06

Sales & Book Value

• Annual Sales: $7.53 million
• Price / Sales: 3.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.04 per share
• Price / Book: 1.59

Miscellaneous

• Outstanding Shares: 9,020,000
• Free Float: 5,265,000
• Market Cap: $29.22 million
• Optionable: No Data
• Beta: 0.26